# AstraZeneca Development Pipeline 27 January 2011

### **Line Extensions**

Compound	Mechanism	Area Under	Phase	Estimated Filing			
·		Investigation		US	EU	Japan	Emerging
Cardiovascular		<u> </u>					
Kombiglyze XR/ Onglyza/	DPP-4 inhibitor + metformin FDC	diabetes	III	Launched	Filed		Filed
metformin IR FDC **	medomin 1 bo						
Dapagliflozin/ metformin FDC <sup>#</sup>	SGLT2 inhibitor + metformin FDC	diabetes	III	1H 2012	1H 2012		
Onglyza SAVOR#	DPP-4 inhibitor	outcomes study	III	2016			
<i>Brilinta</i> PEGASUS-TIMI	ADP receptor antagonist	outcomes study	III	2014	2014	2014	2014
Crestor	statin	outcomes in subjects with elevated CRP	III	Launched	Launched	TBC	Filed
Axanum	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer	III	Filed***	Filed	2014	Filed
Gastrointestinal							
Nexium	proton pump inhibitor	peptic ulcer bleeding	III	Filed	Launched		
Nexium	proton pump inhibitor	GERD	III	Launched	Launched	Filed	Launched
Neuroscience							
Seroquel XR	D <sub>2</sub> /5HT <sub>2</sub> antagonist	major depressive disorder	III	Launched **	Launched **		Launched
Diprivan <sup>#</sup>	sedative and anaesthetic	conscious sedation	III		Launched	2H 2012	Launched
EMLA <sup>#</sup>	local anaesthetic	topical anaesthesia	III		Launched	Filed	Launched
Oncology							
Iressa	EGFR tyrosine kinase inhibitor	1 <sup>st</sup> line EGFR mut+ NSCLC	III		Launched	Filed	Launched
Faslodex	oestrogen receptor antagonist	high dose (500mg) 2 <sup>nd</sup> line advanced breast cancer	III	Launched	Launched	Filed	Filed
Infection							
FluMist/Fluenz	live, attenuated, intranasal influenza virus vaccine	influenza	III	Launched	Filed		
Respiratory & Inf	lammation						
Oxis	long-acting β <sub>2</sub> agonist	COPD	III		Launched	3Q 2011	
Symbicort	inhaled steroid/ long- acting β <sub>2</sub> agonist	COPD	III	Launched	Launched	4Q 2011	Launched
Symbicort	inhaled steroid/ long- acting β <sub>2</sub> agonist	SMART	III		Launched	3Q 2011	Launched

27 January 2011 1

<sup>\*</sup>Partnered product

\* Kombiglyze XR US; Onglyza/metformin IR FDC EU

\*\*Adjunct only, monotherapy withdrawn

\*\*\*CRL Received

## NCEs Phase III/Registration

Compound		Area Under	Phase	Estimated Filing			
		Investigation		US	EU	Japan	Emerging
Cardiovascular							
Brilinta/Brilique	ADP receptor antagonist	arterial thrombosis	III	Filed*	Launched	2013	Approved
Dapagliflozin#	SGLT2 inhibitor	diabetes	III	Filed	Filed	2013	2Q 2011
Neuroscience							
Vimovo <sup>#</sup>	naproxen + esomeprazole	signs and symptoms of OA, RA and AS	III	Launched	Launched		Filed
TC-5214 <sup>#</sup>	neuronal nicotinic receptor modulator	major depressive disorder (adjunct)	III	2H 2012	2015		
Oncology							
Vandetanib (Zactima)	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III	Filed	Filed	3Q 2011	3Q 2011
Zibotentan	endothelin A receptor antagonist	castrate resistant prostate cancer	III	1H 2012	1H 2012		1H 2012
Infection							
MEDI-3250	live, attenuated, intranasal influenza virus vaccine (quadrivalent)	seasonal influenza	III	1H 2011	TBD		
Zinforo <sup>#</sup> (ceftaroline)	extended spectrum cephalosporin with affinity to penicillinbinding proteins	pneumonia /skin infections	III		Filed		3Q 2011
Respiratory & Inflam	mation						
Fostamatinib #	spleen tyrosine kinase (SYK) inhibitor	rheumatoid arthritis	III	2013	2013		2013

<sup>\*</sup>Partnered product
\*CRL received

27 January 2011 2

## NCEs Phases I and II

Compound	Mechanism	Area Under	Phase	Estimated Filing			
		Investigation		US	EU	Japan	Emerging
Cardiovascular					1	<u> </u>	
AZD1656	GK activator	diabetes	l II				
AZD6714	GK activator	diabetes	ı				
AZD8329	11BHSD inhibitor	diabetes/obesity	ı				
AZD7687	diacylglycerol acyl transferase –1 inhibitor	diabetes/obesity	I				
AZD5658	GK activator	diabetes/obesity	ı				
AZD4017	11BHSD inhibitor	glaucoma	I				
Neuroscience							
AZD3480 <sup>#</sup>	alpha4/beta2 neuronal nicotinic receptor agonist	ADHD	II				
AZD6765	NMDA receptor antagonist	major depressive disorder	II	2016	2016		
AZD2066	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	II				
AZD2066	metabotropic glutamate receptor 5 antagonist	major depressive disorder	II				
NKTR-118 <sup>#</sup>	oral peripherally-acting opioid antagonist	opioid-induced constipation	II	2013	2013		
TC-5214 <sup>#</sup>	neuronal nicotinic receptor modulator	major depressive disorder (monotherapy)	II				
TC-5619 <sup>#</sup>	alpha7 neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	II				
AZD1446 <sup>#</sup>	alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease/ADHD	II				
AZD2423	chemokine antagonist	chronic neuropathic pain	II				
AZD3241	myeloperoxidase (MPO) inhibitor	Parkinson's disease	I				
AZD3043#	GABA-A receptor modulator	short acting sedative/ anaesthetic	I				
MEDI-578	anti-NGF MAb	OA pain					
AZD5213	H3AN	Alzheimer's disease/ADHD	I				

<sup>\*</sup>Partnered product

27 January 2011 3

NCEs

Compound         Mechanism         Area Under Investigation         Phase Investigation           Oncology         Recentin         VEGFR tyrosine kinase inhibitor         NSCLC         II         201           Selumetinib" (AZD6244) (ARRY-142886)         MEK inhibitor         solid tumours         II         201           Olaparib         PARP inhibitor         serous ovarian cancer         II         201           AZD1152         aurora kinase inhibitor         haematological malignancies         II           AZD8931         erbB kinase inhibitor         breast cancer chemo combi/solid tumours         II           AZD8461         PARP inhibitor         solid tumours         II           AZD3514         androgen receptor downregulator         prostate cancer         I           AZD7762         CHK1 kinase inhibitor         solid tumours         I           AZD8330"         MEK inhibitor         solid tumours         I           (ARRY 424704)         CAT-8015         anti-CD22 recombinant inmunotoxin         malignancies           MEDI-551         anti-CD19 MAb         haematological inmalignancies           AZD8055         TOR kinase inhibitor         range of tumours         I           MEDI-573"         anti-GF MAb         solid tumours         I     <	6 2016 5 2015 5 2015	5 2016	2016
Discretation   VEGFR tyrosine kinase inhibitor   Selumetinib" (AZD6244) (ARRY-142886)   MEK inhibitor   Selumetinib" (AZD6244) (ARRY-142886)   PARP inhibitor   Serous ovarian cancer   AZD1152   aurora kinase inhibitor   Serous ovarian cancer   II   Discretation   AZD8931   erbB kinase inhibitor   Serous ovarian cancer   II   Discretation   AZD8931   erbB kinase inhibitor   Serous ovarian cancer   II   Discretation   Disc	6 2016 5 2015 5 2015	5 2016	
Recentin   VEGFR tyrosine kinase inhibitor   Selumetinib# (AZD6244)   MEK inhibitor   Solid tumours   II   201	5 2015 5 2015	5 2016	2016
Inhibitor   Selumetinib# (AZD6244) (ARRY-142886)   MEK inhibitor   Solid tumours   II   201	5 2015 5 2015	5 2016	2016
(AZD6244) (ARRY-142886)  Olaparib  PARP inhibitor  cancer  AZD1152  aurora kinase inhibitor  haematological malignancies  breast cancer chemo combi/solid tumours  MEDI-575**  anti-PDGFR-alpha mAb AZD2461  PARP inhibitor  AZD3514  androgen receptor downregulator  AZD8330**  (ARRY 424704)  CAT-8015  anti-CD22 recombinant immunotoxin  MEDI-551  anti-CD19 MAb AZD8055  TOR kinase inhibitor  AZD8055  TOR kinase inhibitor  AZD1480  AZD4547  FGFR tyrosine kinase inhibitor  AZD2014  TOR kinase inhibitor  AZD2046  AZD2046  AZD6244)  (ARRY-142886)  MK2206**  MEDI-3617  anti-ANG-2 MAb  Solid tumours  I  MEKI-ANG-2 MAb  Solid tumours  I  MEKI-BT-BT-BT-BT-BT-BT-BT-BT-BT-BT-BT-BT-BT-	5 2015	5 2016	2016
CARRY-142886    Colaparib   PARP inhibitor   Serous ovarian cancer   AZD1152   aurora kinase inhibitor   haematological malignancies   II   201			2016
AZD1152 aurora kinase inhibitor haematological malignancies combi/solid tumours landonger receptor downregulator (ARRY 424704)  AZD8055 TOR kinase inhibitor solid tumours landingnancies multiplication anti-ICD MAD solid tumours landingnancies lan			2016
AZD8931 erbB kinase inhibitor breast cancer chemo combi/solid tumours  MEDI-575** anti-PDGFR-alpha mAb solid tumours II AZD2461 PARP inhibitor solid tumours I AZD3514 androgen receptor downregulator  AZD7762 CHK1 kinase inhibitor solid tumours I AZD7330* MEK inhibitor solid tumours I AZD8330* MEK inhibitor solid tumours I MEDI-551 anti-CD22 recombinant immunotoxin malignancies  MEDI-551 anti-CD19 MAb haematological malignancies  AZD8055 TOR kinase inhibitor range of tumours I MEDI-573* anti-IGF MAb solid tumours I MEX/AKT inhibitor Solid tumours I MEX/AST inhibitor Solid tumours I MEDI-565 anti-CEA BiTE solid t	5 2015		
Chemo combi/solid tumours   II	5 2015		
AZD2461 PARP inhibitor solid tumours I AZD3514 androgen receptor downregulator  AZD7762 CHK1 kinase inhibitor solid tumours I AZD8330# (ARRY 424704)  CAT-8015 anti-CD22 recombinant immunotoxin malignancies  MEDI-551 anti-CD19 MAb haematological malignancies  AZD8055 TOR kinase inhibitor range of tumours I AZD1480 JAK2 inhibitor solid tumours I AZD1480 JAK2 inhibitor solid tumours I AZD2014 TOR kinase inhibitor solid tumours I AZD2014 Selumetinib (AZD6244) (ARRY-142886) /MK2206# MEDI-3617 anti-ANG-2 MAb solid tumours I AZD5363 AKT inhibitor solid tumours I AZD5365 anti-CEA BiTE solid tumours I Infection AZD9773 anti-TNF-alpha polyclonal antibody serious infections II			
AZD3514 androgen receptor downregulator  AZD7762 CHK1 kinase inhibitor solid tumours I  AZD8330# (ARRY 424704)  CAT-8015 anti-CD22 recombinant immunotoxin malignancies  MEDI-551 anti-CD19 MAb haematological malignancies  AZD8055 TOR kinase inhibitor range of tumours I  MEDI-573# anti-IGF MAb solid tumours I  AZD1480 JAK2 inhibitor myeloproliferative diseases/solid tumours  AZD4547 FGFR tyrosine kinase inhibitor solid tumours I  AZD2014 TOR kinase inhibitor solid tumours I  Selumetinib (AZD6244) (ARRY-142886) /MK2206# MEDI-3617 anti-ANG-2 MAb solid tumours I  AZD363 AKT inhibitor solid tumours I  MEDI-565 anti-CEA BITE solid tumours I  Infection  AZD9773 # anti-TNF-alpha polyclonal antibody  CAZ104# beta lactamase serious infections II			
downregulator  AZD7762 CHK1 kinase inhibitor solid tumours I  AZD8330** (ARRY 424704)  CAT-8015 anti-CD22 recombinant immunotoxim malignancies  MEDI-551 anti-CD19 MAb haematological malignancies  AZD8055 TOR kinase inhibitor range of tumours I  MEDI-573** anti-IGF MAb solid tumours I  AZD1480 JAK2 inhibitor myeloproliferative diseases/solid tumours  AZD4547 FGFR tyrosine kinase inhibitor solid tumours I  AZD2014 TOR kinase inhibitor solid tumours I  Selumetinib (AZD6244) (ARRY-142886) /MK2206** MEDI-3617 anti-ANG-2 MAb solid tumours I  AZD3773 ** anti-CEA BiTE solid tumours I  Infection  AZD9773 ** anti-TNF-alpha polyclonal antibody  CAZ104** beta lactamase serious infections II			
AZD8330* (ARRY 424704)  CAT-8015 anti-CD22 recombinant immunotoxin malignancies  MEDI-551 anti-CD19 MAb haematological malignancies  AZD8055 TOR kinase inhibitor range of tumours I myeloproliferative diseases/solid tumours  AZD1480 JAK2 inhibitor myeloproliferative diseases/solid tumours  AZD4547 FGFR tyrosine kinase inhibitor solid tumours  AZD2014 TOR kinase inhibitor solid tumours  Selumetinib (AZD6244) (ARRY-142886) /MK2206* MEDI-3617 anti-ANG-2 MAb solid tumours  MEDI-365 anti-CEA BITE solid tumours I mileton  AZD9773* anti-TNF-alpha polyclonal antibody  CAZ104* beta lactamase serious infections  I meantalogical malignancies  I myeloproliferative disease/solid tumours  I solid tumours  I solid tumours  I mentalogical malignancies  I myeloproliferative disease/solid tumours  I solid tumours  I myeloproliferative disease/solid tumours  I solid tumours  I mustingancies  I malignancies  I maligna			
(ARRY 424704)Anti-CD22 recombinant immunotoxinhaematological malignanciesMEDI-551anti-CD19 MAbhaematological malignanciesAZD8055TOR kinase inhibitorrange of tumoursMEDI-573**anti-IGF MAbsolid tumoursAZD1480JAK2 inhibitormyeloproliferative diseases/solid tumoursAZD4547FGFR tyrosine kinase inhibitorsolid tumoursAZD2014TOR kinase inhibitorsolid tumoursSelumetinib (AZD6244) (ARRY-142886) /MK2206*MEK/AKT inhibitorsolid tumoursMEDI-3617anti-ANG-2 MAbsolid tumoursAZD5363AKT inhibitorsolid tumoursMEDI-565anti-CEA BiTEsolid tumoursInfectionAZD9773 **anti-TNF-alpha polyclonal antibodyserious infectionsCAZ104**beta lactamaseserious infections			
MEDI-551anti-CD19 MAbhaematological malignanciesIAZD8055TOR kinase inhibitorrange of tumoursIMEDI-573**anti-IGF MAbsolid tumoursIAZD1480JAK2 inhibitormyeloproliferative diseases/solid tumoursIAZD4547FGFR tyrosine kinase inhibitorsolid tumoursIAZD2014TOR kinase inhibitorsolid tumoursISelumetinib (AZD6244) (ARRY-142886) /MK2206*MEK/AKT inhibitorsolid tumoursIMEDI-3617anti-ANG-2 MAbsolid tumoursIAZD5363AKT inhibitorsolid tumoursIMEDI-565anti-CEA BiTEsolid tumoursIInfectionAZD9773*anti-TNF-alpha polyclonal antibodysevere sepsisII201CAZ104**beta lactamaseserious infectionsII			
AZD8055 TOR kinase inhibitor range of tumours I  MEDI-573** anti-IGF MAb solid tumours I  AZD1480 JAK2 inhibitor myeloproliferative diseases/solid tumours  AZD4547 FGFR tyrosine kinase inhibitor solid tumours I  AZD2014 TOR kinase inhibitor solid tumours I  Selumetinib (AZD6244) (ARRY-142886) //MK2206**  MEDI-3617 anti-ANG-2 MAb solid tumours I  AZD5363 AKT inhibitor solid tumours I  MEDI-565 anti-CEA BiTE solid tumours I  Infection  AZD9773** anti-TNF-alpha polyclonal antibody  CAZ104** beta lactamase serious infections II			
AZD8055 TOR kinase inhibitor range of tumours I  MEDI-573** anti-IGF MAb solid tumours I  AZD1480 JAK2 inhibitor myeloproliferative diseases/solid tumours  AZD4547 FGFR tyrosine kinase inhibitor solid tumours I  AZD2014 TOR kinase inhibitor solid tumours I  Selumetinib (AZD6244) (ARRY-142886) //MK2206** MEDI-3617 anti-ANG-2 MAb solid tumours I  AZD5363 AKT inhibitor solid tumours I  MEDI-565 anti-CEA BITE solid tumours I  Infection  AZD9773** anti-TNF-alpha polyclonal antibody  CAZ104** beta lactamase serious infections II			
AZD1480  AZD1480  AZD4547  FGFR tyrosine kinase inhibitor  AZD2014  TOR kinase inhibitor  Selumetinib (AZD6244) (ARRY-142886) /MK2206#  MEDI-3617  AZD5363  AKT inhibitor  MEDI-565  anti-CEA BiTE  Infection  AZD9773 #  anti-TNF-alpha polyclonal antibody  CAZ104#  DAK2 inhibitor  myeloproliferative diseases/solid tumours  I solid			
AZD4547 FGFR tyrosine kinase inhibitor Solid tumours I  AZD2014 TOR kinase inhibitor Solid tumours I  Selumetinib (AZD6244) (ARRY-142886) /MK2206#  MEDI-3617 anti-ANG-2 MAb Solid tumours I  AZD5363 AKT inhibitor Solid tumours I  MEDI-565 anti-CEA BiTE Solid tumours I  Infection  AZD9773 # anti-TNF-alpha severe sepsis II 201  CAZ104# beta lactamase serious infections II			
inhibitor  AZD2014 TOR kinase inhibitor solid tumours I  Selumetinib (AZD6244) (ARRY-142886) /MK2206#  MEDI-3617 anti-ANG-2 MAb solid tumours I  AZD5363 AKT inhibitor solid tumours I  MEDI-565 anti-CEA BiTE solid tumours I  Infection  AZD9773 # anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104# beta lactamase serious infections II			
Selumetinib (AZD6244) (ARRY-142886) /MK2206# Solid tumours I AZD5363 AKT inhibitor Solid tumours I AZD5365 anti-CEA BiTE Solid tumours I Solid tumours I Solid tumours I MEDI-565 AZD5773 anti-TNF-alpha Severe sepsis II Solid tumours I Soli			
(AZD6244) (ARRY-142886) /MK2206 <sup>#</sup> MEDI-3617 anti-ANG-2 MAb solid tumours I AZD5363 AKT inhibitor solid tumours I MEDI-565 anti-CEA BiTE solid tumours I  Infection  AZD9773 ** anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104 <sup>#</sup> beta lactamase serious infections II			
MEDI-3617 anti-ANG-2 MAb solid tumours I AZD5363 AKT inhibitor solid tumours I MEDI-565 anti-CEA BiTE solid tumours I  Infection  AZD9773 anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104 beta lactamase serious infections II			
MEDI-565 anti-CEA BITE solid tumours I  Infection  AZD9773 ** anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104** beta lactamase serious infections II			
Infection  AZD9773 ** anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104** beta lactamase serious infections II			
AZD9773 * anti-TNF-alpha severe sepsis II 201 polyclonal antibody  CAZ104* beta lactamase serious infections II			
polyclonal antibody  CAZ104 <sup>#</sup> beta lactamase serious infections II			
	5 2015	2015	2015
inhibitor/cephalosporin	2013	3	2014
Motavizumab* humanized MAb binding to RSV F protein treatment of RSV in paeds >1 yr			
CXL104 <sup>#</sup> beta lactamase MRSA II (CEF104) inhibitor/cephalosporin	2015	j	
MEDI-534 RSV/PIV-3 vaccine RSV/PIV I prophylaxis			
MEDI-550 pandemic influenza pandemic I virus vaccine influenza prophylaxis			
MEDI-559 RSV vaccine RSV prophylaxis I			
AZD5847 oxazolidinone tuberculosis I antibacterial inhibitor			
AZD9742 BTGT4 IV MRSA I			1

\*Partnered product

27 January 2011 4

## NCEs Phases I and II (continued)

Compound	Mechanism	Area Under	Phase	Estimated Filing			
		Investigation		US	EU	Japan	Emerging
Respiratory & Inf	flammation						
AZD1981	CRTh2 receptor antagonist	asthma/COPD	II				
MEDI-528#	anti-IL-9 MAb	asthma	II				
CAT-354	anti-IL-13 MAb	asthma	II				
AZD3199	iLABA	asthma/COPD	II				
MEDI-563#	anti-IL-5R MAb	asthma	II				
MEDI-545 <sup>#</sup>	anti-IFN-alpha MAb	SLE, myositis	II				
AZD8848	Toll like receptor 7 agonist	asthma	II				
CAM-3001 <sup>#</sup>	anti-GM-CSFR MAb	rheumatoid arthritis	II				
AZD2423	CCR2b antagonist	COPD	II				
AZD8683	muscarinic antagonist	COPD	II				
AZD5423	inhaled SEGRA	COPD	II				
AZD5069	CXCR2	COPD	II				
AZD9819	neutrophil elastase inhibitor	COPD	I				
MEDI-546 <sup>#</sup>	anti-IFNalphaR MAb	scleroderma	1				
MEDI-551	anti-CD19 MAb	scleroderma	I				
MEDI-570 <sup>#</sup>	anti-ICOS MAb	SLE	I				
MEDI-557	RSV MAb – extended half-life	COPD	I				

<sup>\*</sup>Partnered product

27 January 2011 5

# **Development Pipeline - Discontinued Projects vs 29 July 2010**

## Cardiovascular/Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD6370	diabetes
NCE	Lesogaberan (AZD3355)	GERD
NCE	AZD1386	GERD
NCE	AZD2066	GERD
NCE	AZD2516	GERD
NCE	AZD4017	diabetes/obesity
NCE	Certriad	dyslipidaemia

#### **Neuroscience**

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD8529	schizophrenia
NCE	AZD7268	depression/anxiety
NCE	AZD2327	depression/anxiety
NCE	AZD2516	chronic neuropathic pain
LCM	Seroquel XR	generalised anxiety disorder US

Oncology

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD4769	solid tumours
LCM	Faslodex	1 <sup>st</sup> line advanced breast cancer
NCE	Olaparib	gBRCA breast
NCE	MEDI-547	solid tumours

#### Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD7295	Hepatitis C
NCE	Motavizumab	RSV prevention
NCE	MEDI-560	PIV prophylaxis

**Respiratory & Inflammation** 

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD6553	COPD
NCE	AZD9668	COPD

#### Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

27 January 2011 6